Company intelligence / Profile preview

Allertein Therapeutics, LLC

Ownership: Private
Development stage: Phase 1

Overview

Completed a Phase 1 clinical trial (NCT00850668) for EMP-123, a peanut allergy vaccine consisting of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins. The trial evaluated safety and side effects in healthy volunteers and peanut-allergic participants.

Therapeutic areas: Immunology
Modalities: VaccinesRecombinant modified proteins
Industry: Biotech

Drug pipeline

2 assets

emp-123

1 more asset in the full pipeline.

Request access →

Partnerships

National Institute of Allergy and Infectious Diseases

Beyond the preview

Go deeper on Allertein Therapeutics, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allertein Therapeutics, LLC.

Explore the full profile